Advanced Metastatic Prostrate Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

When prostate cancer has metastasized to other organs, it is considered to be at an advanced stage. Prostate cancer that has spread to other organs is advanced cancer. For many years, most men with advanced prostate cancer can lead normal lives. Most frequently, lymph nodes or bones are the sites where prostate cancer spreads. Spreading to the lungs or liver is also typical. Estimates from GLOBO CAN 2018 indicate that 1,276,106 new cases of prostate cancer were reported globally in 2018, with developed nations having a higher incidence. The use of diagnostic tests varies globally, which is reflected in variations in infection rates. The growth of prostate cancer can be accelerated by male hormones, particularly testosterone. Advanced prostate cancer growth is slowed by lowering testosterone levels and activity. The mainstay of treatment for advanced prostate cancer is hormone (endocrine) therapy, also known as androgen ablation or androgen suppression therapy. It serves as the primary therapy for metastatic prostate cancer.

Description

When prostate cancer has metastasized to additional body organs, it is considered to be advanced. A cancer in its advanced stages is metastatic prostate cancer. Many years can be spent living a normal life for men with advanced prostate cancer. Most frequently, lymph nodes or bones are the sites of prostate cancer spread. Spreading to the lungs or liver is also typical. Though it rarely happens, it can occasionally spread to other organs like the brain. Symptoms of advanced prostate cancer include pain in the bones and difficulty urinating. The symptoms of advanced prostate cancer are not always present. Depending on where the cancer has spread, the symptoms that do manifest will vary in type. Growth of the prostate cancer can result in urinary issues, such as the need to urinate frequently, poor urine flow, bleeding, or discomfort. Lower back, upper thighs, and buttocks pain are symptoms of bone metastasis in cancer patients. Fatigue and unexpected weight loss are additional symptoms of advanced prostate cancer.

Advanced Metastatic Prostrate Cancer (Epidemiology)

Estimates from GLOBO CAN 2018 indicate that 1,276,106 new cases of prostate cancer were reported globally in 2018, with developed nations having a higher incidence. The use of diagnostic tests varies globally, which is reflected in variations in infection rates. Men over the age of 65 have the highest incidence of prostate cancer, and mortality rates are also strongly correlated with age. Compared to white men, African-American men have higher rates of infection and aggressive prostate cancer. Regional and societal differences affect prostate cancer incidence. Prostate cancer accounted for 71% of all new cancer cases in men in 2018, with 1,276,106 new cases reported globally. World-wide disparities exist in the incidence of prostate cancer. North America (73.7) and Oceania (79.1) were the two regions with the highest age standard ratios (ASR) per 100,000 people, respectively. Europe (62.1) was third. Africa and Asia, on the other hand, had lower rates than developed nations (26.6 and 11.5, respectively). The incidence varied by 190-fold between the highest incidence (France, Guadeloupe, 189.1) and the lowest incidence (Bhutan, 1.0). As people age, prostate cancer cases rise. Prostate cancer will only be discovered in 1 in 350 men under the age of 50, but it will be found in 1 in 52 men between the ages of 50 and 59. About 60% of men over the age of 65 experience it. Uncertainty surrounds the causes of these nation-to-nation variations. PSA testing is responsible for regional variations in prostate cancer incidence. Prostate cancer, for instance, was the most frequently diagnosed cancer in men in Europe in 2018, accounting for 24% of all new cancer cases with an estimated 450,000 new cases. Due to the fact that there were 164,690 new cases of prostate cancer in 2018, prostate cancer is the second most prevalent type of cancer in the country. The widespread use of PSA testing may lead to an overdiagnosis of prostate cancer in the US and Europe in the range of 20-40%.

Advanced Metastatic Prostrate Cancer -Current Market Size & Forecast Trends

The prostate cancer therapeutics market was valued at $7.28 billion in 2024, with a focus on androgen receptor inhibitors and radioligand therapies. The market is projected to grow at a CAGR of ~5%, reaching over $12.84 billion by 2035.

Prostate cancer can grow more quickly when male hormones, particularly testosterone, are present. The development of advanced prostate cancer is slowed by lowering testosterone levels and activity. The mainstay of treatment for advanced prostate cancer is hormone (endocrine) therapy, also referred to as androgen ablation or androgen suppression therapy. It is the first line of defense against metastatic prostate cancer. Endocrine therapy frequently provides short-term relief from the signs and symptoms of advanced prostate cancer. Endocrine therapy can typically lower PSA levels and tumor size in male patients. The prostate gland produces a substance called prostate-specific antigen, and an abundance of it indicates the presence of prostate cancer. The field of treating prostate cancer has grown significantly over the last ten years. Advanced prostate cancer encompasses not just mCRPC but also mHSPC and even some localized diseases with high-risk characteristics. These developments go hand in hand with a better comprehension of the genetic complexity of these cancers and the application of sophisticated functional imaging techniques that are identifying more patients with metastatic disease who had not yet been diagnosed. Many of the newly created medications use various genetic delivery systems. However, by utilizing current treatments earlier in the course of the disease, more advantages can be realized. Even more exciting are recent initiatives to combine local therapies to enhance outcomes in patients with metastatic disease. Although advanced prostate cancer is challenging to treat, we anticipate significant advancements in the care of these patients as we use real-time biomarkers to predict response and broaden treatment options to address the complexity of this illness. New findings from two sizable clinical trials presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting indicate that the landscape of treatments for metastatic prostate cancer is evolving and expanding. Cancer is still a hormone, which men respond to suppressive therapy, also known as castration-sensitive prostate cancer. The ENZAMET trial examined enzalutamide (Xtandi), and TITAN examined apalutamide (Erleada). In both studies, the use of associated medications in conjunction with androgen deprivation therapy (ADT) significantly increased both the overall life expectancy of men and the amount of time before their cancer got worse for them.

Report Highlights

Advanced Metastatic Prostrate Cancer - Current Market Trends

Advanced Metastatic Prostrate Cancer - Current & Forecasted Cases across the G8 Countries

Advanced Metastatic Prostrate Cancer - Market Opportunities and Sales Potential for Agents

Advanced Metastatic Prostrate Cancer - Patient-based Market Forecast to 2035

Advanced Metastatic Prostrate Cancer - Untapped Business Opportunities

Advanced Metastatic Prostrate Cancer - Product Positioning Vis-a-vis Competitors' Products

Advanced Metastatic Prostrate Cancer - KOLs Insight